Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.76 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.76 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.72 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | CDK9 | P50750 | 1/20 | 0.67 |
| ▸ | CLK1 | P49759 | 1/20 | 0.67 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.67 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.67 |
| ▸ | KIT | P10721 | 5/20 | 0.66 |
| ▸ | AXL | P30530 | 1/20 | 0.62 |
| ▸ | CDK8 | P49336 | 1/20 | 0.62 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.61 |
| ▸ | SGK1 | O00141 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171362 | 0.88 | NTRK1 (0.70) | NTRK1DYRK1APIK3CACCNT1CCNA2 | |
| SCHEMBL3769860 | 0.87 | DYRK1A (0.75) | NTRK1DYRK1APIK3CACCNT1CCNA2 | |
| SCHEMBL3764839 | 0.87 | AXL (0.83) | NTRK1DYRK1APIK3CAMAP3K11CLK1 | |
| SCHEMBL18576768 | 0.85 | NTRK1 (1.00) | NTRK1DYRK1APIK3CAMAP3K11CLK1 | |
| SCHEMBL3762873 | 0.84 | MAP3K11 (0.73) | NTRK1DYRK1APIK3CAMAP3K11CDK2 | |
| SCHEMBL722564 | 0.84 | MAP3K11 (1.00) | NTRK1DYRK1APIK3CAMAP3K11CLK1 | |
| SCHEMBL17951904 | 0.84 | DYRK1A (0.74) | NTRK1DYRK1APIK3CACCNT1CCNA2 | |
| SCHEMBL3760212 | 0.83 | AXL (0.80) | NTRK1DYRK1APIK3CACDK2KIT | |
| SCHEMBL26175478 | 0.82 | KIT (0.67) | NTRK1DYRK1APIK3CACCNT1CCNA2 | |
| SCHEMBL16344153 | 0.82 | GSK3B (0.73) | NTRK1DYRK1APIK3CACCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | claimed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| WO-2021006707-A1 | USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES | 한양대학교 산학협력단 | 2021-01-14 | — | — | WO | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | NTRK1 964/4885DYRK1A 378/4885PIK3CA 335/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | NTRK1 997/4885DYRK1A 360/4885PIK3CA 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.